AtriCure (ATRC) and Its Competitors Head-To-Head Analysis

AtriCure (NASDAQ:ATRC) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its competitors? We will compare AtriCure to similar businesses based on the strength of its risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Profitability

This table compares AtriCure and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AtriCure	2.52%	4.01%	3.03%
AtriCure Competitors	-304.20%	-315.07%	-22.11%

Earnings & Valuation

This table compares AtriCure and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
AtriCure	$534.53 million	-$11.45 million	191.77
AtriCure Competitors	$1.90 billion	$136.31 million	5.82

AtriCure’s competitors have higher revenue and earnings than AtriCure. AtriCure is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for AtriCure and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	1	4	6	1	2.58
AtriCure Competitors	4291	10577	18359	831	2.46

AtriCure currently has a consensus price target of $61.80, indicating a potential upside of 7.42%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 20.64%. Given AtriCure’s competitors higher possible upside, analysts clearly believe AtriCure has less favorable growth aspects than its competitors.

Insider and Institutional Ownership

99.1% of AtriCure shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 4.0% of AtriCure shares are owned by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

AtriCure has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, AtriCure’s competitors have a beta of 2.57, indicating that their average stock price is 157% more volatile than the S&P 500.

Summary

AtriCure beats its competitors on 7 of the 13 factors compared.

AtriCure Company Profile

AtriCure, Inc. is a medical technology company that develops and sells products for the treatment of atrial fibrillation and other conditions addressed through cardiac surgery. Its technologies are used by surgeons and other medical professionals in hospital settings. The company’s products include surgical ablation systems designed to treat irregular heart rhythms and devices for managing the left atrial appendage, a small pouch in the heart associated with stroke risk in some patients with atrial fibrillation.